About Archimica
Archimica is a Healthcare company based in Sandycroft (United Kingdom) founded in 1999, and was acquired by PI Health Sciences in April 2023. It develops nucleic acid analysis tools for research and clinical diagnostics applications. Its chief executive, as recorded, is Norbert Dieterich. Archimica offers products and services including Cytarabine, Hydroxyurea, and Mianserin. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Genomics. Its legal entity is Archimica S.p.A.
Company details
Archimica was established in 1999 in Sandycroft, United Kingdom, within the biotechnology sector focused on molecular diagnostics. Nucleic acid analysis tools are created for research and clinical use, including next-generation real-time polymerase chain reaction systems. Operations center on advancing diagnostic technologies, with the company accessible via archimica.com. Leadership is provided by CEO Norbert Dieterich, supporting applications in healthcare and scientific research.
- Headquarters Sandycroft, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website archimica.com
- Social LinkedIn
- Acquired by PI Health Sciences (Apr 2023)
- Legal Name Archimica S.P.A.
- InvestorsEuticals
& 1 more
- Acquired by
Products & Services of Archimica
Archimica offers a comprehensive portfolio of products and services, including Cytarabine, Hydroxyurea, and Mianserin.
Nucleoside analogue for cancer treatment applications
Modified urea used in medical therapies
Tetracyclic compound for pharmaceutical purposes
Investors in Archimica
Archimica has secured backing from 2 investors. Prominent investors backing the company include Euticals and PI Health Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specializes in CRO and CDMO services for medicinal chemistry and API manufacturing. | 2021 | pihealthsciences.com | Udaipur, India | |
APIs, custom synthesis, and fine chemicals are developed and manufactured. | 1984 | euticals.com | Milano, Italy |
Investor details for Archimica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Archimica
1 people are tracked at Archimica (1 in leadership).
| Name | Role | Group |
|---|---|---|
Norbert Dieterich | CEO | Leadership |
Complete people profiles for Archimica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Archimica
3 dated milestones of Archimica across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Archimica is founded.
- Exit Acquired by Euticals.
- Exit Acquired by PI Health Sciences.
Web traffic of Archimica
The website of Archimica (archimica.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 246.4% vs previous month
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Archimica (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Archimica
Complete news archive for Archimica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Archimica
Archimica was founded in 1999.
Archimica is headquartered in Sandycroft, United Kingdom.
Norbert Dieterich is the CEO of Archimica, as recorded in our data.
Archimica was established in 1999 in Sandycroft, United Kingdom, within the biotechnology sector focused on molecular diagnostics. Nucleic acid analysis tools are created for research and clinical use, including next-generation real-time polymerase chain reaction systems. Operations center on advancing diagnostic technologies, with the company accessible via archimica.com. Leadership is provided by CEO Norbert Dieterich, supporting applications in healthcare and scientific research.
Archimica offers Cytarabine, Hydroxyurea, and Mianserin.
Archimica has 2 investors. Key investors include Euticals, and PI Health Sciences.
Archimica operates through Archimica S.P.A..
Yes. Archimica was acquired by PI Health Sciences in April 2023.